Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by Pandoraon Dec 25, 2024 11:44am
44 Views
Post# 36377197

RE:VPT 2025

RE:VPT 2025
From the Q3  Review of Dec. 9th:

"In early May we submitted VMS+ v4 to FDA for 510(k) clearance using an expedited process and were advised to resubmit under the standard process due to the novelty of certain product features. This was achieved by the end of that month and we received the review in August. To address several of the questions we elected to engage an external company to conduct cybersecurity testing, and contracted a regulatory consultancy to assist with questions related to AI. Our written follow up is largely complete and we anticipate receiving the additional information within the next 2-3 weeks, following which we will submit the package to FDA. This has taken longer than was originally forecast but we believe that completeness of information is important to the success of the submission."

Is this the normal dragging of the feet at the FDA?
<< Previous
Bullboard Posts
Next >>